# A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

> **NCT02586051** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 24 (actual)

## Conditions studied

- Kidney Failure, Chronic

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Intravenous Immunoglobulin

## Key facts

- **NCT ID:** NCT02586051
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-19
- **Primary completion:** 2018-11-26
- **Final completion:** 2018-11-26
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586051, "A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02586051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*